611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Cancer
Resources
Basic InformationLatest News
1 in 4 U.S. Seniors With Cancer Has Had It BeforeStool-Based Protein Combos Can Improve CRC ScreeningNAFLD Linked to Increased Cancer Incidence RateCancer Survivors Can Develop PTSD, TooDrug Combo Doesn't Lengthen Glioblastoma SurvivalHealth Tip: Talking With Your Child's Cancer-Care TeamER- Breast CA Risk Up for African-Americans With T2DMHow to Do a Skin Cancer Body CheckStudy Untangles Disparity in Colon Cancer Survival RatesDiabetes May Be Driving High Rates of Breast Cancer in Black WomenOral Chemotherapy Parity Laws Offer Some Financial ProtectionHealth Tip: Recognize Symptoms of Oral CancerBreast Cancer Recurrences Steady After Therapy CessationLow-Fat Diet May Cut Pancreatic Cancer Risk for Overweight Older WomenKnow the Signs of Ovarian Cancer and Your RisksHealth Tip: Accept Help if Your Child Has CancerAverage Cost of Care in Year After Ovarian Cancer Surgery ~$100KRisk of Breast Cancer's Return Can Linger for DecadesASCO Issues Statement Regarding Alcohol and CancerEven Light Drinking May Raise Your Cancer RiskWaiting Even a Month to Remove Melanoma Can Be DeadlyIUD May Lower Cervical Cancer RiskYoga May Give Lung Cancer Patients, Caregivers a BoostFiber Tied to Lower Mortality in Those With Colorectal CancerIncidence of Early-Stage Breast CA, CRC Up With ACA AdoptionZelboraf Approved for Rare Blood CancerWhy Many Breast Cancer Patients Short-Circuit Their TreatmentCould a Common Blood Thinner Lower Cancer Risk?Are You Sure That's What the Doctor Said About Your Leukemia?Patients' Gut Bugs May Play Role in Cancer CareEven Advanced Breast Cancer Patients Gain From ExerciseFiber-Rich Diet Boosts Survival From Colon CancerDo Rising Cancer Drug Prices Warrant Regulation?Liposuction May Ease Limb Swelling in Cancer PatientsAre Some Heartburn Meds Tied to Stomach Cancer?Speed Up the 'Cancer Moonshot,' Doctors UrgeInternists Key to Identifying Need for Genetic Counseling for CancerCalquence Approved for Mantle Cell LymphomaShould Colon Cancer Screening Start at 45, not 50?Multidisciplinary Model Cuts Treatment Delay in Head, Neck CA70-Gene Signature Impacts Treatment Decisions in Breast CAGastric Cancer Incidence Down, Survival UpGene Therapy May Fight Brain Cancer's ReturnHealth Tip: Being a Cancer CaregiverMany High-Risk Women Skip MRI Breast Cancer ScreeningsSurvival Odds Improving for Lung Cancer PatientsJoan Lunden's Breast Cancer Journey: 'You Feel So Vulnerable'Mechanism ID'd for Chemo-Related Peripheral NeuropathySwedish Massage May Reduce Cancer-Related FatigueRamucirumab Shows Promise in Care of Advanced Gastric Cancer
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

Multivitamin Use May Cut Risk of Chemo-Induced Neuropathy


HealthDay News
Updated: Sep 13th 2017

new article illustration

WEDNESDAY, Sept. 13, 2017 (HealthDay News) -- Multivitamin use before diagnosis of breast cancer is associated with reduced risk of symptoms of chemotherapy-induced peripheral neuropathy, according to a study published online Sept. 1 in the Journal of the National Cancer Institute.

Gary R. Zirpoli, Ph.D., from the Roswell Park Cancer Institute in Buffalo, N.Y., and colleagues examined use of dietary supplements before and during treatment in relation to CIPN using data from questionnaires completed by 1,225 breast cancer patients. The authors assessed supplement use in relation to CIPN; they used the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v. 3.0) and the self-reported Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity (FACT/GOG-Ntx) subscale.

The researchers found that there was an association for multivitamin use before diagnosis with reduced symptoms of CIPN (CTCAE-adjusted odds ratio, 0.6 [95 percent confidence interval, 0.42 to 0.87]; FACT/GOG-Ntx-adjusted OR, 0.78 [95 percent confidence interval, 0.61 to 1]). There was a marginal inverse correlation for use during treatment with CIPN (CTCAE-adjusted odds ratio, 0.73 [95 percent confidence interval, 0.49 to 1.08]; FACT/GOG-Ntx-adjusted odds ratio, 0.77 [95 percent confidence interval, 0.6 to 0.99]). There was no significant correlation for other supplement use, either before diagnosis or during treatment, with CIPN.

"Multivitamin use could be a surrogate for other related behaviors that are the actual drivers of the association with reduced CIPN," the authors write.

The study was partially funded by Amgen.

Abstract/Full Text (subscription or payment may be required)